Journal: Oncotarget

Article Title: AMPK activation by Tanshinone IIA protects neuronal cells from oxygen-glucose deprivation

doi: 10.18632/oncotarget.23391

Figure Lengend Snippet: The stable SH-SY5Y cells, expressing AMPKα1 shRNA (“S1/2”), or scramble control shRNA (“shC”) ( A – D ) as well as expressing CRISPR/Cas-9-AMPKα1 (“AMPKα1-KO”) or CRISPR/Cas-9 control (“CRISPR-C”), were pre-treated with 10 μM of Tanshinone IIA (“ThIIA”), with or without oxygen glucose deprivation (OGD, for 4 hours) and re-oxygenation (ODGR); AMPKα1 mRNA level was tested by qRT-PCR assay (A and E ); Listed proteins in total cell lysates were shown (B and F ); Cell survival and cell death were tested by MTT assay (C and G ) and LDH release assay (D and H ), respectively. Data were presented as mean ± SD ( n = 5). * P < 0.05 vs. “Mock” group. # P < 0.05 vs. “shC” cells (C–D) or “CRISPR-C” cells (G and H). Experiments in this figure were repeated three times, and similar results were obtained.

Article Snippet: The small guide RNA (sgRNA) targeting human AMPKα1 was based on the Optimized CRISPR Design application ( http://crispr.mit.edu/ ), which was provided by Genepharm (Shanghai, China).

Techniques: Expressing, shRNA, Control, CRISPR, Quantitative RT-PCR, MTT Assay, Lactate Dehydrogenase Assay